Atlas Trials

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Clinical trial NCT05785208 · UNKNOWN

Trial details

NCT number
NCT05785208
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2022-06-28
Primary completion
2024-02-28
Enrollment
122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.